Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 23:8:32.
doi: 10.3389/fneur.2017.00032. eCollection 2017.

The Efficacy and Tolerability of the Clonidine Transdermal Patch in the Treatment for Children with Tic Disorders: A Prospective, Open, Single-Group, Self-Controlled Study

Pan-Pan Song  1 , Li Jiang  1 , Xiu-Juan Li  1 , Si-Qi Hong  1 , Shuang-Zi Li  1 , Yue Hu  1
Affiliations

The Efficacy and Tolerability of the Clonidine Transdermal Patch in the Treatment for Children with Tic Disorders: A Prospective, Open, Single-Group, Self-Controlled Study

Pan-Pan Song et al. Front Neurol. .

Abstract

Background: To evaluate the efficacy and tolerability of a clonidine transdermal patch in the treatment of children with tic disorders (TD) and to establish a predictive model for patients.

Methods: Forty-one patients who met the inclusion criteria entered into 12 weeks of prospective, open, single-group, self-controlled treatment with a clonidine transdermal patch. The Yale Global Tic Severity Scale (YGTSS) was employed before therapy (baseline) and at 4, 8, and 12 weeks after therapy.

Results: (1) The total effect rates of treatment with a clonidine transdermal patch were 29.27, 53.66, and 63.41% at 4, 8, and 12 weeks, respectively. Compared with the baseline, the differences were significant at three different observation periods. (2) Compared to the level of 25% reduction, there were significant decreases in the score-reducing rate of motor tic and total tic severities at 12 weeks. (3) If the disease course was ≤24 months and the motor tic score was <16 at the baseline, there was an effective rate of 100% for treatment with the clonidine transdermal patch. If the disease course was ≤24 months and the motor tic score was >16, there was an effective rate of 57.1%. If the disease course was >24 months and the clinical classification was chronic TD, there was an effective rate of 62.5%. If the disease course was >24 months and the clinical classification was Tourette's syndrome, 90% of the patients were invalid. (4) The main adverse events were rash, slight dizziness, and headache.

Conclusion: (1) When patients were pretreated with a D2-dopamine receptor antagonist that was ineffective or not tolerated well, switching to a clonidine transdermal patch treatment was effective and safe. (2) A clonidine transdermal patch could be a first-line medication for mild and moderate TD cases that are characterized by motor tics.

Keywords: children; clonidine transdermal patch; efficacy; prediction model; tic disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Growing method of classification and regression tree.
Figure 2
Figure 2
The importance of independent variables affecting treatment.
See this image and copyright information in PMC

References

    1. Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, Münchau A. Pharmacological treatment of tic disorders and Tourette syndrome. Neuropharmacology (2013) 68:143–9.10.1016/j.neuropharm.2012.05.043 - DOI - PubMed
    1. Houeto JL, Giré P. Tics and Tourette syndrome: diagnosis, course and treatment principles. Presse Med (2008) 37:263–70.10.1016/j.lpm.2007.11.007 - DOI - PubMed
    1. Olson LL, Singer HS, Goodman WK, Maria BL. Tourette syndrome: diagnosis, strategies, therapies, pathogenesis, and future research directions. J Child Neurol (2006) 21:630–41.10.1177/08830738060210080601 - DOI - PubMed
    1. Stern J. Update on tic disorders and Tourette syndrome. Paediatr Child Health (2010) 20:411–5.10.1016/j.paed.2010.03.013 - DOI
    1. Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review: pharmacological treatment of tic disorders – efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev (2013) 37:1162–71.10.1016/j.neubiorev.2012.09.008 - DOI - PMC - PubMed

LinkOut - more resources